Merrill Upgrades King Pharmaceuticals to 'Buy'

Analyst Gregory Gilbert is pleased with the drug maker's return to profit, and its efforts to manage inventory

Merrill Lynch upgraded King Pharmaceuticals (KG ) to buy from neutral.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.